Steven Feldman is a partner at Hueston Hennigan. He helps clients navigate a broad range of high-stakes litigation, including complex commercial disputes, intellectual property matters and challenging class actions. Mr. Feldman, who was named a “Rising Star” by Super Lawyers every year since 2016, uses his experience at all stages of litigation to develop creative and aggressive case strategies for his clients, with the goal of obtaining their desired result – whether it be a favorable settlement or winning at trial. Not only does this place his clients in the best position to prevail, it also avoids unnecessary disputes and minimizes discovery costs. Mr. Feldman’s clients have included companies such as Amgen, T-Mobile and BHP Billiton, as well as high-profile individuals such as Alec Baldwin and Bill Koch.
Mr. Feldman has deep experience in the courtroom: In addition to serving as a member of several successful trial teams, including the team that won a $12 million punitive damages verdict and liability findings on all counts in favor of his client following a three-week federal jury trial in the Southern District of New York, he has argued and won significant motions for clients in state and federal courts in California and New York. Mr. Feldman also has a strong record of defeating challenging class actions, obtaining numerous dismissals at the pleadings stage or earlier. Recently, Mr. Feldman obtained the decertification of a consumer class action on behalf of a leading manufacturer of natural health products and nutritional supplements, in a decision Law360 called one of the “Class Certification Rulings Every Litigator Needs to Know.”
Mr. Feldman began his career Davis Polk & Wardwell in New York City, where he focused on complex business litigation, and served as a law clerk to the Honorable Jacqueline H. Nguyen of the U.S. Court of Appeals for the Ninth Circuit. While in law school, he also served as an extern to the Hon. Charles R. Breyer of the U.S. District Court in San Francisco and to the Hon. Robert D. Sack of the U.S. Court of Appeals for the Second Circuit.
Mr. Feldman serves on the board of directors of the Association of Business Trial Lawyers and the Harvard Law School Alumni Association of Los Angeles. He also moderates “The Insight Roundtable,” a series he created and developed, featuring one-on-one interviews with leading jurists, lawyers and business executives. Recent interviewees have included the general counsels of The Walt Disney Company, NBC Universal, Toyota, and Kleiner Perkins Caufield & Byers.
- Koch v. Greenberg: Won an eight-figure punitive damages verdict and liability findings on all claims of fraud, deceptive business practices and false advertising following a highly publicized, three-week jury trial in New York federal court in a suit related to the defendant’s sale of counterfeit fine wine to our client.
- T-Mobile v. Huawei et al.: Won a seven-figure verdict and liability findings on behalf of T-Mobile, following a three-week jury trial alleging trade secret theft and breach of contract by China’s largest phone manufacturer.
- Alec Baldwin v. Mary Boone et al.: Obtained seven-figure settlement, representing a full trial victory, on behalf of Alec Baldwin, in a high-profile art fraud case against the Mary Boone Gallery (See “Why Alec Baldwin is $1 Million Richer Today” in The New York Times, “Alec Baldwin Settles …” in the Daily Journal, and “Alec Baldwin’s Legal Tussle Over Art” in The New Yorker).
- Goldcrest Film Distribution v. Summit Entertainment: Won the dismissal of a multimillion-dollar contractual dispute over alleged deceptive accounting practices used to calculate profit participations for the “Twilight” movie saga, on behalf of Lionsgate subsidiary Summit Distribution LLC.
Class Action Defense
- Otero v. Zeltiq Aesthetics: Won dismissal of putative class action against Allergan subsidiary Zeltiq Aesthetics, alleging that customers of the company’s high-profile CoolSculpting fat-freezing system were deceived by marketing materials that described the medical device as having been “cleared,” but not “approved” by the U.S. Food and Drug Administration. (See Law360: Allergan’s Fat-Freezing Unit Freed From False Ad Claims)
- Shin v. Umeken USA et al.: Won dismissal of putative class action brought against our client, a leading health and dietary supplement company, alleging claims of false advertising, misbranding and RICO, as well as violations of the Federal Food Drug and Cosmetics Act.
- Ruhnke v. Allergan: On behalf of client Allergan, obtained a low five-figure settlement in a putative consumer class action litigation seeking over $85 million in damages. The settlement came on the eve of Plaintiffs’ certification papers being due, and following aggressive offensive discovery that revealed facts damaging to Plaintiffs’ case. The suit alleged that Allergan’s leading skincare and cosmetics line is in violation of the Food Drug and Cosmetics Act, and that the product was being marketed in a way that violates false advertising and unfair competition laws.
- Hammock et al v. Nutramarks Inc. et al: Won dismissal of federal putative class action regarding homeopathic medicines, following aggressive and strategic offensive discovery that revealed the inadequacy of multiple lead plaintiffs and legal deficiencies in the overall case. Plaintiffs agreed to voluntarily dismiss the action just days before their motion for class certification was due.
- Lopez v. Caskers LLC: Obtained dismissal of a putative consumer class action alleging violations of California’s Automatic Renewal Law, on behalf of Caskers LLC, the leading e-commerce company focusing on the curation and sale of craft spirits.
- CEH v. U.S. International Trading Corp: Obtained dismissal of a putative consumer class action alleging that our client violated false advertising laws by misleadingly labeling a consumer product as “organic.”
- In re Amgen Inc. Securities Litigation: Represented Amgen, the world’s largest biopharmaceutical company, in a national securities fraud class action alleging misstatements and omissions related to several of Amgen’s most important drugs.
- CEH v. Nutraceutical Corp. et al.: Representing Nutraceutical in an important appellate matter regarding the scope of plaintiffs’ suits brought under California’s Proposition 65.